(1) Background: Excess weight in the form of adiposity plays a key role in the pathogenesis of cardiometabolic diseases. Lifestyle modifications that incorporate continuous energy restriction (CER) are effective at inducing weight loss and reductions in adiposity; however, prescribing daily CER results in poor long-term adherence. Over the past decade, intermittent fasting (IF) has emerged as a promising alternative to CER that may promote increased compliance and/or improvements in cardiometabolic health parameters independent of weight loss. (2) Methods: This paper presents a secondary analysis of data from a 12-week intervention investigating the effects of a twice-weekly fast (5:2 IF; IFT group) and CER (CERT group) when combined with resistance exercise in 34 healthy participants (17 males and 17 females, mean BMI: 27.0 kg/m², mean age: 23.9 years). Specifically, changes in cardiometabolic blood markers and ratings of hunger, mood, energy and compliance within and between groups were analysed. Dietary prescriptions were hypoenergetic and matched for energy and protein intake. (3) Results: Both dietary groups experienced reductions in total cholesterol (TC; mean reduction, 7.8%; p < 0.001), low-density lipoprotein cholesterol (LDL-C; mean reduction, 11.1%; p < 0.001) and high-density lipoprotein cholesterol (mean reduction 2.6%, p = 0.049) over the 12 weeks. Reductions in TC and LDL-C were greater in the IFT group after adjustment for baseline levels and change in weight. No significant changes in markers of glucose regulation were observed. Both groups maintained high levels of dietary compliance (~80%) and reported low levels of hunger over the course of the intervention period. (4) Conclusions: Secondary data analysis revealed that when combined with resistance training, both dietary patterns improved blood lipids, with greater reductions observed in the IFT group. High levels of compliance and low reported levels of hunger throughout the intervention period suggest both diets are well tolerated in the short-to-medium term.

Background: Recent evidence suggests that sarcopenia and subsequent changes in muscle mass and functional outcomes are linked to disruption to the gastrointestinal microbiota composition and/or function via the microbiota-gut-muscle axis. Despite growing interest, few studies have systemically analysed (1) the relationship between the gut microbiota, muscle mass and physical performance and (2) the effects of gut-modulating dietary interventions on these outcomes within older individuals with or without sarcopenia. Methods: Four electronic databases (PubMed, MEDLINE, Embase and Scopus) were searched for articles published from the year 2004 until July 2023. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were followed. Revised Cochrane Risk of Bias (RoB 2.0) and Joanna Briggs Institute (JBI) critical appraisal checklist were utilised to evaluate the risk of bias within intervention and observational studies, respectively. Results: A total of 20 studies (14 observational and 6 interventional) involving 4071 older participants (mean age 69.9 years, 51.6% female) were included. There was significant heterogeneity regarding interventions and outcome measures used in these studies. Correlations between microbiota diversity and composition and sarcopenia-related functional outcomes were observed. Interventional studies targeting the gut microbiota resulted in improved muscle strength, body composition or physical function in some, but not all, studies. Conclusions: Despite limitations in the studies reviewed, the findings provide further evidence that the development of sarcopenia is likely influenced by an altered gut microbial environment and that interventions targeting the microbiome could hold therapeutic potential for the treatment or management of sarcopenia.